Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …

Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …

PURPOSE In previous analyses of the MURANO study, fixed-duration venetoclax plus
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United
States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small …

Disease overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …